新华鲜报|超100种！我国医保罕见病用药创新高

Group 1 - The new national medical insurance drug list includes over 100 rare disease medications, covering more than 50 disease types, providing hope for more patients [1][3] - The drug Lenvatinib, approved for Langerhans cell histiocytosis, has a high monthly treatment cost of approximately 17,000 yuan, making it unaffordable for most patients [1][3] - The inclusion of Lenvatinib in the insurance list not only treats Langerhans cell histiocytosis but also extends to pediatric patients with neurofibromatosis type I, lowering the age limit for treatment from 3 years to 2 years [3][4] Group 2 - The national medical insurance has included 19 innovative drugs, including 6 rare disease medications, in a new commercial insurance model to improve accessibility [4] - Measures such as the publication of clinical guidelines for 86 rare disease types and the establishment of a national rare disease diagnosis and treatment collaboration network are being implemented to enhance patient care [4][5] - The combination of policy support and community initiatives, such as the "Little Cat Cheer Up" app for parents of rare disease children, is fostering a supportive environment for patients [4][5]